Prevention of Venous Thromboembolism Disease in Emergency Departments

NCT ID: NCT01212393

Last Updated: 2018-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-09-30

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The appropriate use of thromboprophylaxis in medical patients admitted to hospital can substantially reduce the overall burden of disease due to venous thromboembolism. However, the use of thromboprophylaxis in medical setting appears to be generally poor leaving at-risk patients unprotected.

We aim to analyse the incidence of symptomatic thromboembolic disease following hospitalisation in medical setting and the efficacy of a multicomponent prevention approach in emergency department including systematic evaluation of thrombosis risk factors and remembers of thrombophylaxis indications and modalities for acutely ill medical patients.

Design: cluster randomized interventional study - Observational study at patient level

Setting: 30 French emergency departments

Patients: Patients over 40 years old admitted in participating emergency departments and hospitalized for acute medical reasons.

Main judgment criteria: the rate of symptomatic thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Method:

At the end of an observational period of a week, centers will be randomized in two groups: intervention or current practice. In the intervention group, centers will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment. We will propose no change in current practice in the other group.

Primary outcome: the rate of symptomatic venous thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.

All possible thromboembolic events, severe haemorrhages and deaths will be analysed by an adjudication committee blinded of group assignation. Sudden death without obvious cause according to the adjudication committee will be considered as possible fatal pulmonary embolism.

Sample size: We calculated sample size on the basis of primary outcome. Assuming the participation of 30 centers (15 in each group), an intracluster correlation of 0.01, a rate of symptomatic thromboembolic events or severe haemorrhage of 5% in the current practice group, we need a sample of 16170 patients (8085 in each group) to detect a 1.5 percentage absolute difference between the 2 groups (3.5% in the intervention group) with a power of 80% and a significance level of 5%.

Considering a rate of patients hospitalized less than 48 hours around 5% and of lost of follow-up around 3%, we anticipated to include 16500 patients for the main analysis and 18000 patients for the overall study.

Secondary outcomes:

* The appropriateness of thromboprophylaxis in the overall population and according to group assignation:

* Number of patients needing prevention treatment according to international recommendations and who have an appropriate treatment.
* Number of patients without indication of thromboprophylaxis and who do not receive a treatment
* The rate of symptomatic venous thromboembolic events during a formal 3-months follow-up after hospital admission

* in all included patients
* in patients hospitalized at least 48 hours.
* inpatients hospitalized less than 48 hours
* The rate of thromboembolic events

* in patients who had an appropriate thromboprophylactic treatment
* in patients who had an inappropriate thromboprophylactic treatment
* in patients who had no thromboprophylactic treatment
* The rate of severe haemorrhage

* in patients who had an appropriate thromboprophylactic treatment
* in patients who had an inappropriate thromboprophylactic treatment
* in patients who had no thromboprophylactic treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Quality of Health Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

reminders

reminders

Intervention Type BEHAVIORAL

In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.

current practice group

no intervention

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

reminders

In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age over 40 years
* Emergency department admission for non-traumatic reason
* Hospitalization in medical setting

Exclusion Criteria

* patients less than 40 years old
* patients hospitalized in a facility which doesn't participate to the study
* 3 months follow-up not possible
* patients refusing that their personal data are used for medical research
* patients refusing to be reach for the 3 months follow-up
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre-Marie ROY, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

UH Angers

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UH Agen

Agen, , France

Site Status

H Argenteuil

Argenteuil, , France

Site Status

UH Besançon

Besançon, , France

Site Status

H Bethune

Béthune, , France

Site Status

H Bobigny

Bobigny, , France

Site Status

UH Ambroise Pare

Boulogne-Billancourt, , France

Site Status

UH Brest

Brest, , France

Site Status

H Chateauroux

Châteauroux, , France

Site Status

H Clermont Ferrand

Clermont-Ferrand, , France

Site Status

H Compiegne

Compiègne, , France

Site Status

UH Dijon

Dijon, , France

Site Status

UH Grenoble

Grenoble, , France

Site Status

UH La Reunion

La Réunion, , France

Site Status

UH Marseille

Marseille, , France

Site Status

UH Metz Thionville

Metz, , France

Site Status

UH Nantes

Nantes, , France

Site Status

UH Nimes

Nîmes, , France

Site Status

UH la pitié salpetriere

Paris, , France

Site Status

H Cochin

Paris, , France

Site Status

UH Bichat

Paris, , France

Site Status

UH Hotel Dieu

Paris, , France

Site Status

UH Poitiers

Poitiers, , France

Site Status

UH Rennes

Rennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Roy PM, Rachas A, Meyer G, Le Gal G, Durieux P, El Kouri D, Honnart D, Schmidt J, Legall C, Hausfater P, Chretien JM, Mottier D; PREVENU study group. Multifaceted Intervention to Prevent Venous Thromboembolism in Patients Hospitalized for Acute Medical Illness: A Multicenter Cluster-Randomized Trial. PLoS One. 2016 May 26;11(5):e0154832. doi: 10.1371/journal.pone.0154832. eCollection 2016.

Reference Type DERIVED
PMID: 27227406 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHRC 2008-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.